Pacific Biosciences of California Inc’s recently made public that its Officer CHRISTIAN HENRY acquired Company’s shares for reported $0.49 million on Feb 18 ’25. In the deal valued at $1.88 per share,259,909 shares were bought.
Then, MARK VAN OENE bought 100,773 shares, generating $189,252 in total proceeds.
Before that, Van Oene Mark sold 34,405 shares. Pacific Biosciences of California Inc shares valued at $69,980 were divested by the insider at a price of $2.03 per share. As a result of the transaction, Van Oene Mark now holds 1,597,454 shares, worth roughly $2.99 million.
UBS downgraded its Pacific Biosciences of California Inc [PACB] rating to a Neutral from a a Buy in a research note published recently. JP Morgan also remained covering PACB and has decreased its forecast on April 22, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. Goldman revised its rating on April 18, 2024. It rated PACB as “a Neutral” which previously was an “a Buy”.
Price Performance Review of PACB
On Tuesday, Pacific Biosciences of California Inc [NASDAQ:PACB] saw its stock jump 1.08% to $1.87. Over the last five days, the stock has gained 40.60%. Pacific Biosciences of California Inc shares have risen nearly 2.19% since the year began. Nevertheless, the stocks have fallen -71.23% over the past one year. While a 52-week high of $6.83 was reached on 01/08/25, a 52-week low of $1.16 was recorded on 02/12/25. SMA at 50 days reached $1.8104, while 200 days put it at $1.7831.
Levels Of Support And Resistance For PACB Stock
The 24-hour chart illustrates a support level at 1.7633, which if violated will result in even more drops to 1.6567. On the upside, there is a resistance level at 1.9933. A further resistance level may holdings at 2.1167. The Relative Strength Index (RSI) on the 14-day chart is 58.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.1890, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 24.05%. Stochastics %K at 74.26% indicates the stock is a holding.
The most recent change occurred on December 14, 2023 when Stephens began covering the stock and recommended ‘”an Overweight”‘ rating along with a $11 price target.
